Watchers | 15,503 |
52-Wk Low | $668.00 |
52-Wk High | $853.97 |
Market Cap | $104.52B |
Volume (M) | 560,217.00 |
52-Wk High | $853.97 |
52-Wk Low | $668.00 |
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Regeneron Pharmaceuticals, Inc. market cap is $104.52B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Regeneron Pharmaceuticals, Inc. 52 week high is $853.97 as of December 02, 2023.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Regeneron Pharmaceuticals, Inc. 52 week low is $668.00 as of December 02, 2023.
Regeneron Pharmaceuticals, Inc. stock price today is $814.86.
Regeneron Pharmaceuticals, Inc. stock price yesterday was $823.81.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Regeneron Pharmaceuticals, Inc.’s P/E ratio is 23.24.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Regeneron Pharmaceuticals, Inc. P/B ratio is 3.5599.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Regeneron Pharmaceuticals, Inc.'s EBITDA is 17.86.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Regeneron Pharmaceuticals, Inc. 50-day moving average is $813.12.
Regeneron Pharmaceuticals, Inc. has 11,851 employees.
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.